Clinical Trial

A Study of CS23546 in Subjects With Advanced Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objectives of this study are to characterize the safety and tolerability of CS23546 and to evaluate the pharmacokinetic (PK) characteristics and recommended phase 2 dose (RP2D) of CS23546 in subjects with advanced tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-05; most recent amendment 2026-04-03.
Status change: Not Yet Recruiting → Recruiting 2024-04-21
Trial Details
NCT Number NCT06245122
Lead Sponsor Chipscreen Biosciences, Ltd.
Conditions Advanced Tumors
Enrollment 156 participants
Start Date 2024-03-27
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-06